A Positive Move Towards Fewer Liver Transplants

The government’s announcement for the inclusion of two new drugs to treat the hepatitis C virus (HCV) in the pharmaceutical benefits scheme has been welcomed by Professor Geoff McCaughan, Head of Liver Injury and Cancer at the Centenary Institute and Head of Liver Transplant Unit, Royal Prince Alfred Hospital.

Geoff McCaughan

Professor McCaughan is a world leader in hepatitis and liver disease research

The subsidy essentially means these very expensive drugs have become more accessible for those undergoing treatment and marks the first breakthrough in a decade for treatment of this chronic condition.

Professor McCaughan said that “this is a giant leap forward in reducing the need for liver transplants in Australia and it’s a great day for patients who suffer from chronic hepatitis C in this country.

“The introduction of these drugs means that we can cure up to 75 per cent of patients with genotype 1 hepatitis C – the most common strain of the disease. Treatment time will also be cut in half for many patients, from one year to six months.”

Continue reading